Global PARP Inhibitors Cancer Therapy Market and Clinical Trials Insight 2028

  • No. of Pages: 240
  • Publish Date: May-2022
  • Category: Pharmaceutical and Healthcare
Electronic Access Single User
$3300 $2800
Electronic Access Multi User
$6000 $4800

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

Global PARP Inhibitors Cancer Therapy Market and Clinical Trials Insight 2028 Report Highlights:


  • Global PARP Inhibitors Cancer Therapy Market opportunity: > USD 6 Billion
  • Commercially Available PARP inhibitors: > 5 Drugs
  • Comprehensive Clinical Insight On More Than 35 PARP Drug In Clinical Trials
  • Global PARP Clinical Trials Insight by Company, Country, Indication and Phase
  • Market Indicators Till 2028
  • Approved Drugs Dosage, Sales, Patent, Price Insight
  • Approved Drugs Sales Forecast Till 2028
  • Global and Regional Market Analysis
  • Regional Analysis Based On Drug Approvals:  US, Europe, Chna and Japan


Genomic studies have revealed that altered DNA damage response (DDR) is an emerging hallmark and enabling characteristic of cancer, associated with both tumor initiation and progression. In addition, as anti-cancer cytotoxic agents such as chemotherapy and radiation function to induce DNA damage in cancer cells, alterations in DDR have role in resistance to these therapies. Therefore, scientists believed that targeting of DDR will significantly improve treatment and survival of cancer patients. One prominent DDR family of proteins which is being investigated is poly (ADP-ribose) polymerase (PARP) enzymes which have emerged as potential therapeutic target for the management of cancer. 


Scientists have developed several PARP inhibitors which work by binding to the catalytic domain of the PARP enzyme. PARP inhibitors (olaparib, niraparib, rucaparib and talazoparib) are currently approved as a monotherapy by US FDA and EMA. Currently marketed PARP Inhibitors are approved for treating breast cancer, ovarian cancer, fallopian tube cancer; primary peritoneal cancer, and pancreatic cancer. In addition to this, a large number of PARP inhibitors are present in clinical development which is expected to gain approval during the forecast period.


For instance, Senaparib (IMP4297) developed by Impact Therapeutics is an investigational agent which works by targeting PARP (poly-ADP ribose polymerase). The company is currently conducting two phase-1 trials of senaparib in China and Australia. Till date, about 100 patients have been treated with Senaparib and initial results have demonstrated encouraging response. In comparison to other PARP inhibitors currently on the market and in clinical trials; senaparib has a wider therapeutic window and a better safety profile. This potentially makes senaparib more suitable for patients taking the drug chronically such as in maintenance therapy. Moreover, researchers believed that the combination of senaparib with other cancer targeting agents will also demonstrate promising results. Therefore, senaparib has the potential to be the best-in-class PARP inhibitor in the forthcoming years. 


Apart from its role as monotherapy, PARP inhibitors have also shown to be promising in combination with other therapeutics including immunotherapy, PI3K, MEK and CDK 4/6 inhibitors. Furthermore, studies have revealed that combining PARP inhibitors with DNA damaging agents including chemotherapy and radiotherapy could prevent repair of treatment induced damage. These approaches have been widely investigated in ovarian and breast cancer. The coming years is expected to witness dominance of combinational therapy in PARP inhibitors market owing to its enhanced efficacy, specificity, and targetability in the management of wide range of cancers.  


As per our report findings, the global PARP inhibitor market is expected to surpass US$ 6 Billion by 2028. Several factors including rising geriatric population with increased risk of developing cancer, increasing emphasis on research and development, and large number of ongoing clinical trials are the major factors boosting the growth of market. Further, favorable government policies for life science companies and government funding are also expected to boost the PARP inhibitor therapy demand in near future.


The Global PARP Inhibitors Cancer Therapy Market and Clinical Trials Insight 2028 report is a comprehensive analysis of a variety of factors that are prevalent in the PARP Inhibitors. The report provides in-depth analysis on the globally approved PARP inhibitors along with their patent expiration, pricing, dosage, sales analysis, and forecast. It also gives a detailed description of drivers and opportunities in PARP Inhibitor market that helps the consumers and potential customers to get a clear vision and take effective decisions. In addition to this, it comprises various strategic planning techniques, which promotes the way to define and develop the framework of the industries.

Need custom market research solution? We can help you with that too.